- Home
- LU vs RARE Comparison
LU vs RARE Comparison
Compare LU & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LU | RARE |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LU | RARE |
|---|---|---|
| Price | $2.69 | $24.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $73.11 |
| AVG Volume (30 Days) | 1.1M | ★ 4.2M |
| Earning Date | 03-23-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,671,260,668.00 | $630,598,000.00 |
| Revenue This Year | N/A | $19.68 |
| Revenue Next Year | $1.62 | $19.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.63 |
| 52 Week Low | $2.25 | $18.41 |
| 52 Week High | $4.57 | $46.50 |
Technical Indicators
Market Signals| Indicator | LU | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 52.51 | 44.02 |
| Support Level | $2.63 | $22.00 |
| Resistance Level | $2.75 | $24.65 |
| Average True Range (ATR) | 0.09 | 1.22 |
| MACD | 0.01 | 0.48 |
| Stochastic Oscillator | 63.41 | 84.01 |
Price Performance
Historical ComparisonAbout LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.